

Ketamine-Induced Hallucinations

Albert R. Powers III^{a, c} Mark G. Gancsos^{a, c} Emily S. Finn^b Peter T. Morgan^{a, c}
Philip R. Corlett^{a, c}

^aDepartment of Psychiatry, Yale School of Medicine, ^bInterdepartmental Neuroscience Program, Yale University, and ^cConnecticut Mental Health Center, New Haven, Conn., USA

Key Words

Ketamine · Hallucinations · Predictive coding · Psychosis · Computational psychiatry · Prediction · Psychosis

Abstract

Background: Ketamine, the NMDA glutamate receptor antagonist drug, is increasingly employed as an experimental model of psychosis in healthy volunteers. At subanesthetic doses, it safely and reversibly causes delusion-like ideas, amotivation and perceptual disruptions reminiscent of the aberrant salience experiences that characterize first-episode psychosis. However, auditory verbal hallucinations, a hallmark symptom of schizophrenia, have not been reported consistently in healthy volunteers even at high doses of ketamine. **Sampling and Methods:** Here we present data from a set of healthy participants who received moderately dosed, placebo-controlled ketamine infusions in the reduced stimulation environment of the magnetic resonance imaging (MRI) scanner. We highlight the phenomenological experiences of 3 participants who experienced particularly vivid hallucinations. **Results:** Participants in this series reported auditory verbal and musical hallucinations at a ketamine dose that does not induce auditory hallucination outside of the scanner. **Conclusions:** We interpret the observation of ketamine-induced auditory verbal hallucinations in the context of the reduced perceptual environment of the MRI scanner

and offer an explanation grounded in predictive coding models of perception and psychosis – the brain fills in expected perceptual inputs, and it does so more in situations of altered perceptual input. The altered perceptual input of the MRI scanner creates a mismatch between top-down perceptual expectations and the heightened bottom-up signals induced by ketamine. Such circumstances induce aberrant percepts, including musical and auditory verbal hallucinations. We suggest that these circumstances might represent a useful experimental model of auditory verbal hallucinations and highlight the impact of ambient sensory stimuli on psychopathology.

© 2015 S. Karger AG, Basel

Introduction

The introduction of phencyclidine (PCP) and its pharmacological relative, ketamine, as anesthetic agents in the late 1950s and early 1960s was followed in short order by the recognition of their psychotomimetic effects [1]. In the years since, ketamine has been employed as an experimental model of psychosis, reproducing the positive and negative symptoms of schizophrenia transiently, reversibly and safely in healthy nonpsychotic volunteers [2]. A noncompetitive NMDA (N-methyl-D-aspartate) receptor antagonist, ketamine has been instrumental in

establishing a potential role for glutamatergic signaling in psychosis [3, 4]. Inconsistently present in the constellation of ketamine-induced symptoms, however, are auditory verbal hallucinations, a hallmark of schizophrenia described in 60–80% of patients [5, 6]. Here we evaluate descriptions of perceptual abnormalities produced by acute exposure to PCP and ketamine and present 3 cases of hallucinatory experiences with ketamine administration in a functional neuroimaging setting. We attempt to explain the inconsistent presence of hallucinations following ketamine within a predictive coding framework.

Table 1 highlights the perceptual abnormalities reported in placebo-controlled investigations of the arylcyclohexamine family of noncompetitive NMDA antagonists, of which ketamine and PCP are members. Notable similarities among the studies include the amplification or sharpening of sensory input [2, 7, 8] and alteration of the spatial and temporal relationships within or among individual sensory streams [1, 2, 9, 10]. Hallucinations are described only intermittently and, in many cases, vaguely enough for the discerning reader to suspect conflation with sensory illusions – that is, distortions or amplifications of stimuli that are actually present [8, 11]. Some of the earliest accounts of PCP and ketamine responses describe memory-driven dissociative experiences that were rich in sensory detail. Luby et al. [1] described so-called ‘hypnogogic states’ produced by PCP:

The subjects reported feeling as though they were in some specific setting and were able to describe it in detail. While the reports typically had reference to past events, they were expressed as though the experiences were taking place at the moment.

The authors provide a striking example – a participant who experienced the full sensory array associated with a scene from his childhood:

He stated that he was in his third-grade classroom, which he described elaborately, including the recognition of an old friend in the classroom.

This is echoed in a later description of prominent eidetic imagery (but otherwise a lack of outright hallucinations) by Stone and Pilowsky [12] during ketamine administration in healthy volunteers. Similarly, the earliest descriptions of ketamine’s psychotomimetic effects include the presence of memory-like ‘frank hallucinations’, although these are not characterized in more detail [13]. Indeed, discerning such dissociative or illusory experiences from ‘true’ hallucinations has posed a practical problem in this literature. Some, like Newcomer et al. [10], solved the dilemma by rating all perceptual abnor-

malities as hallucinations in standard scales like the Brief Psychiatric Rating Scale (BPRS [14]) while stating separately that these may not represent true hallucinations [10], while others have maintained that true hallucinatory experiences have not arisen in trials of ketamine administration and that the perceptual effects of ketamine are better characterized as illusions or sensory distortions [2, 7, 8].

Despite this seeming paucity of reports describing hallucinations in the setting of controlled administration of ketamine, several case reports do describe hallucinations during acute treatment with ketamine and in the hours, days and weeks following dosing. One such case report describes vivid visual hallucinations associated with recovery from ketamine anesthesia [15] with spontaneous resolution and intact memories for the said phenomena (typically referred to as emergence phenomena [13]). A similar emergence pattern was observed in another study [16] meant to examine the rate of psychiatric adverse reactions in patients in a general hospital setting receiving intravenous ketamine at subanesthetic doses (mean = 0.19 mg/kg/h) for pain control. Here the authors reported hallucinations in 4 of 50 patients, although they did not elaborate further on the nature of these phenomena. Intriguingly, these hallucinatory emergence phenomena have at times been reported to extend beyond the acute phase of administration. One case report describes an incident in which an 11-year-old boy experienced a vivid visual hallucination of his grandmother at his bedside during emergence from ketamine anesthesia but also sporadically for 5 days following initial recovery from anesthesia while lying in bed [17]. In another pediatric case, Meyers and Charles [18] describe the experience of a 3-year-old girl who reported malicious red and green lights in the room 30 min after recovery from ketamine anesthesia but continued to report similar phenomena at least 1 day afterward and even developed fears of traffic lights. In this case, nightmares involving her hallucinatory experience persisted for 1 year after ketamine anesthesia. Similarly, Fine and Finestone [19] report vivid dreams in 80% of patients given ketamine at anesthetic doses and provide 3 cases of visual hallucinations in these patients, who continued to experience flashback-like visual disturbances in the weeks following administration. The first case is that of a vivid dream of riding a rocket downward, with recurrence of these sensations for 3 weeks afterward, but only when descending a staircase. The second case was similar, with floating/flying sensations noted during recovery from ketamine and a 1-week history of the same sensation afterward. The last case de-

Table 1. Characteristics and findings of systematic studies of psychotomimetic properties of PCP and ketamine

Authors [Ref.]	Year	Design	Sample	NMDA antagonist	Dose	Perceptual findings
Luby et al. [1]	1959	Nonplacebo-controlled PCP administration	9 TD 9 SZ	PCP	0.1 mg/kg i.v. for 12 min	Perceived limb lengthening; feelings of flying; complete change in setting to past experience; 'sensory experiences were overvalued if not eroticized'; mild diminution in auditory and visual acuity
Lawes [7]	1963	2 × 3 dosage group vs. environmental stimulation level	8 TD	PCP	Group A (n = 5): 5 mg p.o. Group B (n = 3): 10 mg p.o.	Amplification or alteration in quality of sounds, sharpening of vision, room expansion; body 'lightness'; dose-response relationship observed
Oye et al. [60]	1992	Double-blind crossover with 4 doses of 2 enantiomers, 2 placebo doses	6 TD	Ketamine	S-ketamine: 0.05, 0.1, 0.15, 0.2 mg/kg i.v. R-ketamine: 0.2, 0.4, 0.6, 0.8 mg/kg i.v.	Blurred vision, visual field narrowing; preoccupation with irrelevant environmental stimuli; sound amplification
Krystal et al. [2]	1994	Double-blind placebo-controlled 2-dose level crossover	19 TD	Ketamine	Low dose: 0.1 mg/kg i.v. High dose: 0.5 mg/kg i.v.	Increased perceived intensity or closeness within a discrete spatial field; no outright hallucinations noted
Vollenweider et al. [41]	1997	Within-subject placebo-controlled counterbalanced trial	10 TD	Ketamine	Loading dose of 15 mg i.v. racemic ketamine followed by continuous infusion of 0.014–0.02 mg/kg/min	Visual illusions as well as complex hallucinations present with S-ketamine administration; auditory hyperacusis but no hallucinations noted
Bowdle et al. [11]	1998	Single-blind placebo-controlled crossover	10 TD	Ketamine	Intravenous administration set to keep plasma concentration at 0, 50, 100, 150, 200 ng/ml in progressive steps	Hallucinations as rated on a visual analog scale ('I heard voices or sounds that were not real') differed significantly between ketamine and saline and correlated with plasma concentration; these experiences are not described further
Newcomer et al. [10]	1999	Double-blind placebo-controlled 3-dose level	15 TD	Ketamine	Loading: 0.27, 0.081, 0.0243 mg/kg i.v. Maintenance: 0.00225, 0.000675 and 0.0002025 mg/kg/min	Visual distortions (e.g. hands perceived as shrunken, 'shadow of a body falling' noted in window); no outright hallucinations noted
Lahti et al. [40]	2001	2 × 2 group by placebo vs. drug crossover	18 TD 17 SZ	Ketamine	0.3 mg/kg i.v.	Formed auditory hallucinations (e.g. articulated voices) in SZ subjects (despite low levels of positive symptoms outside drug administration), and in a minority of TD subjects; visual and olfactory hallucinations in both groups
Gouzoulis-Mayfrank et al. [9]	2005	Double-blind 2-drug, 2-dose crossover	15 TD	Ketamine and DMT	Ketamine: 0.1 mg/kg i.v. (low) and 0.2 mg/kg i.v. (high) DMT: 0.15 mg/kg (low) and 0.3 mg/kg (high)	Limb lengthening and other somatic distortions; visual hallucinations present in 1 subject on ketamine; auditory distortions but no hallucinations reported; DMT with more pronounced visual and auditory phenomena and musical hallucinations and whispers occurred in 2 cases; visual hallucinations on DMT were present in all subjects at high dose levels
Pomarol-Clotet et al. [8]	2006	Experimental case series for phenomenological description	15 TD	Ketamine	Intravenous administration set to keep plasma concentration at 100 ng/ml, then 200 ng/ml	Increased sensitivity to noise and increased brightness of colors; loss of visual depth perception; alterations in perceived size, shape or position of body parts; 1 participant reported sensing the presence of more people than were visibly present and hearing voices that were unable to be accounted for by those present

TD = Typically-developing; SZ = schizophrenia.

scribes vivid dreams of seeing faceless people around the recovery bed followed by 1 week of experiencing the same visions after lying down in bed. All of these experiences resolved spontaneously after several months.

Despite the well-documented nature of the perceptual disturbances often experienced with ketamine administration, there remains significant discrepancy regarding the presence, characteristics and environmental settings necessary for the experience of hallucinations induced by NMDA antagonists. Here we present data from participants taking part in a pharmacological functional neuroimaging study [20], highlighting the phenomenological experiences of 3 participants who experienced particularly vivid hallucinations, and discuss the implications of these findings for the role of predictive coding in hallucinations.

Methods

The present data were drawn from a double-blind, placebo-controlled, randomized, within-subject design. Subjects completed 3 visits, prior to which they were randomly assigned to pretreatment with a different dose of a partial allosteric modulator of metabotropic glutamate receptors (0 mg/placebo, 50 or 180 mg). In the magnetic resonance imaging (MRI) scanner, during saline and ketamine administration, subjects completed a delayed spatial working memory task described in detail in a prior publication [21].

Subjects

All subjects provided informed consent approved by the Institutional Review Board at Yale University. A total of 20 healthy, neurologically and psychiatrically intact right-handed volunteers (10 male) with a mean \pm SD age of 27.5 ± 6.3 years were recruited from the local community by advertisement. Subjects were screened using an initial telephone interview and subsequent personal interview. Psychiatric or physical illness, head injury, drug or alcohol dependence, and smoking were excluding factors, as were family history of psychiatric illness and alcohol problems.

Infusion Protocol

Subjects were administered racemic ketamine (1 mg/ml; Bedford Laboratories) intravenously via initial bolus (0.23 mg/kg to be administered over 1 min) followed by subsequent continuous infusion of 0.58 mg/kg/h for 75 min. Prior studies from our laboratory using very similar infusion paradigms consistently produced plasma ketamine levels during infusion of approximately 200 ng/ml [22] and reliably and transiently produced positive symptoms, negative symptoms and cognitive impairments redolent of schizophrenia [23]. This infusion approach produces stable effects across repeated test days on most behavioral outcome measures [24] and does not appear to be associated with persisting negative effects [23].

Clinical Measures

Subjects underwent clinical rating scales before and after infusions. Here we focused on the Positive and Negative Syndrome

Scale (PANSS [25]), which is designed to assess positive, negative and general psychotic symptoms. It should be noted that, unlike other uses of the PANSS in the setting of ketamine administration [10], our approach rated perception in the absence of physical stimulus (true hallucinations) on the P3 hallucinatory behavior item and did not take into account perceptual distortions or illusions. It should also be noted that these ratings reflected phenomena in any of the sensory systems (auditory, visual, olfactory/gustatory, or somatic) and did not necessarily reflect the presence of auditory hallucinations (although see vignettes below, in which the hallucinations were primarily auditory, sometimes visual and somatic and rarely olfactory/gustatory).


We also report phenomenological descriptions from 3 participants who experienced auditory verbal and musical hallucinations while in the MRI scanner on ketamine (rated on the PANSS as a score of 3 or higher). We only considered quantitative and qualitative data from study visits when individuals were pretreated with 0 mg of metabotropic glutamate receptor partial allosteric modulator (thus, 'placebo' here refers to the period of saline infusion, which always preceded the period of ketamine infusion). Other clinical and neuroimaging data will be the subject of future reports.

Results

Ketamine-Induced Symptoms

Analysis of symptom scores was performed on the entire sample of 19 participants. Compared with ratings prior to the infusion, ketamine induced positive, negative and general symptoms (fig. 1). Repeated-measures analysis of variance with drug (placebo/ketamine) and symptom (positive, negative and general) factors revealed a significant main effect of drug ($F_{1, 19} = 45.8, p = 0.001$) and symptom ($F_{2, 38} = 263.2, p = 0.0001$) and a significant drug \times symptom interaction ($F_{1.8, 34.5} = 6.9, p = 0.004$, applying Huynh-Feldt correction for nonsphericity of the covariance matrices). Post hoc tests revealed that ketamine engendered more positive than negative symptoms ($t = 2.9, d.f. = 19, p = 0.008$) and more general than negative ($t = 13.3, d.f. = 19, p = 0.0001$) or positive symptoms ($t = 13.3, d.f. = 19, p = 0.0001$). For the purposes of the present study, we examined the positive symptoms more closely with a similar analysis – repeated-measures analysis of variance with drug (placebo/ketamine) and symptom dimension (delusions, hallucinations, conceptual disorganization, hostility, persecution, excitement, grandiosity, and unusual thought content). This revealed a main effect of drug ($F_{1, 19} = 36.4, p = 0.0001$) and symptom dimension ($F_{5, 92} = 8.4, p = 0.009$) and a significant drug \times symptom dimension interaction ($F_{1, 19} = 8.79, p = 0.008$, applying Huynh-Feldt correction). Post hoc tests revealed that hallucinations were the most common symptom, with hallucination scores exceeding those of the other PANSS

Fig. 1. Ketamine-induced symptoms. **a** Total PANSS subscale scores for all 19 participants tested after placebo and ketamine administration. **b** PANSS component scores for all positive symptoms (P1–P7) and 1 general symptom dimension (G9). Analysis revealed a main effect of drug ($F_{1, 19} = 36.4, p = 0.0001$) and symptom dimension ($F_{5, 92} = 8.4, p = 0.009$) and a significant drug \times symptom dimension interaction. Post hoc tests revealed that hallucinations were the most common symptom, with hallucination scores exceeding those of the other PANSS items. Error bars = 1 SEM.



items (e.g. P3, hallucinatory behavior, vs. P1, delusions, $t = 5.01, d.f. = 19, p = 0.001$).

Case Descriptions

Case 1: Subject 23 (Hallucinations Component Score, P3 = 5, Total Positive Symptoms Score = 16)

This 21-year-old female graduate student volunteered for our research study and passed our screen for safety and appropriateness of participation. She described herself as a soccer fan and had been watching a lot of soccer the day before the infusion (including a penalty shoot-out in the World Cup). One of the authors (P.R.C.) had discussed this shoot-out with her be-

fore the infusion. As the infusion began, she felt that the computer screen in front of her turned into a soccer pitch and she could see the players on it. She described how the head coil transformed into a soccer goal. She felt transported to a specific soccer game, the 2005 FIFA Champion's League Final in Istanbul, Turkey, between Liverpool FC and AC Milan – believing she was there. She could hear the Liverpool fans in the crowd singing 'You'll Never Walk Alone'. She felt irritated because in the first half of the game Liverpool conceded 3 goals, but she knew what would happen after half-time (Liverpool scored 3 goals to tie the game and won in a penalty shoot-out) and felt superior to the others in the crowd

around her because they did not know this and she would not share it with them.

Case 2: Subject 30 (Hallucinations Component Score, P3 = 5, Total Positive Symptoms Score = 16)

This 21-year-old female graduate student volunteered and qualified for our research study. When the infusion began and her first blood sample was drawn (for plasma ketamine assay), she became concerned that something had gone awry with the experiment. She thought that she might have died and that her left arm had disappeared. She reported thinking more about life and its purpose and that her philosophy was 'somewhere between Dr. Who and the Matrix' (she had been watching Dr. Who the day before). She asked: 'What if existence isn't real? What if everyone is a figment of my imagination?' She described having less control over her thoughts and that one of the authors (P.R.C.) had taken control of her thoughts whilst she stood back. At the same time, she described being able to predict the trials of a working memory task before they happened. She felt disconnected from her body and she imagined she was talking whilst in the scanner, receiving the infusion. When told that she had not been talking during the infusion, she related that her thoughts were being broadcast out loud. She reported hearing the voices of friends and family members talking, reassuring her about her future. She described how the noise of the MRI scanner came to sound like drums and then more complete music – music she had not heard before. Overall, she rated her experiences as pleasant and enjoyable.

Case 3: Subject 42 (Hallucinations Component Score, P3 = 4, Total Positive Symptoms Score = 17)

This 30-year-old male real estate agent participated in our study having passed our screening telephone call and in-person interview. He described the ketamine infusion as being 'like a tidal wave' that made him think more about black holes and cosmology. He described feeling confused and 'befuddled', which made him distrust the study team that was working with him but at the same time feeling that we were his 'oldest and best friends'. He described the world becoming 'spaghetti-like' – vertical lines pervaded his vision. His inner speech, the thoughts in his head, became very clear at times and dulled at others. Being in the scanner, he saw part of his face reflected in the mirror used to present tasks and felt he looked distorted, as though he had undergone plastic surgery ('I looked like Joan Rivers'). He felt at times he was being brainwashed ('like in *A Clockwork Orange*' – the novel by Anthony Burgess and the movie by Stanley Kubrick) and

that although he was stationary in the scanner, he was also moving. He described the noise of the scanner turning into music and that the music changed his vision – he heard the Nutcracker Suite and saw the wooden soldiers, he heard Yellow Submarine by the Beatles and saw the animated characters from that movie, and he heard the entirety of the album Diamond Dogs by David Bowie.

Discussion

Despite its reputation as a hallucinogen, subanesthetic ketamine does not consistently produce frank hallucinations. We report 3 cases of placebo-controlled ketamine administration that produced frank musical and auditory verbal hallucinations accompanied by dissociation and a loss of insight. The experiences of these 3 participants, while discussed in detail here because of the finer points of their phenomenology, are consistent with the larger sample of subjects participating in this paradigm and thus represent a departure from the historically inconsistent inclusion of hallucinations among the symptoms produced by ketamine.

We now attempt to reconcile these disparate reports by considering how hallucinations arise within the information-processing hierarchy of the brain and why the relatively sparse sensory environment of the MRI scanner might be particularly conducive to the genesis of hallucinations under ketamine. A number of recent works [26–28] have posited a Bayesian framework for understanding the relationship between top-down predictive coding and bottom-up inference in perceptual processing. We propose that ketamine perturbs the balance between priors, prediction errors and their precision [29], such that bottom-up noise is enhanced and top-down priors attempt to accommodate the noise [27]. There are rodent [30] and human [31] data that support this notion.

Additionally, quantitative approaches to ketamine's effects on sensory processing have produced results that match qualitative reports of sensory amplification. Plourde et al. [32] determined that, unlike most general anesthetics, ketamine produces an increase in auditory event-related gamma-band oscillations in patients administered anesthetic doses. Similar increases in gamma-band oscillations have also been demonstrated in somatosensory-evoked potentials in subjects administered subanesthetic ketamine [13]. In the context of predicted normal ambient input, top-down priors can be mobilized, resulting in delusion-like interpretations of aberrant salience, but not hallucinations [27] (fig. 2, left pan-




Fig. 2. Influence of environmental conditions and ketamine administration on perceptual processing. In the absence of ketamine and under everyday environmental conditions (top left panel), there is a balanced equilibrium between bottom-up (upward arrow) and top-down (downward arrow) processing in perceptual inference. If environmental information is minimized, resulting in a decreased signal (via bottom-up AMPA-dependent glutamate signaling; top right panel, narrowed upward arrow), improved perceptual performance is achieved by increasing the (neuromodulator-mediated) gain on top-down priors in perceptual inference

(darkened downward arrow). In the presence of ketamine (bottom panels), which blocks NMDA-mediated top-down signaling and boosts AMPA-mediated bottom-up signaling (bottom left panel; narrow downward arrow, widened upward arrow), increased sensory salience is observed and delusion-like ideas result. However, in the setting of minimized environmental stimulation, the (normally adaptive) increased gain on top-down priors seen in this setting combines with increased bottom-up prediction errors to produce experience-related hallucinations.

els). However, in the reduced perceptual environment of the MRI scanner (fig. 2, right panels), perceptual expectations are already being violated, which triggers prediction error responses that are exacerbated by ketamine. A more robust top-down response is mounted (as a result of the sensory isolation) and hallucinations result. We have proposed that this enhanced top-down response is mediated by the slow neuromodulators dopamine and acetylcholine [27], which have been shown to mediate attentional gain on incoming sensory information [33] and encode salience of environmental stimuli [34].

Efforts in computational modeling of perception have had some success using simple neural network models to help explain the occurrence of hallucinations in cases of sensory deprivation like Charles-Bonnet syndrome [28], in which deafferentation of lower levels of the visual processing hierarchy gives rise to homeostatic mechanisms that increase excitability of the network and result in spontaneous activation of complex perceptual representations in deep association layers. This is plausible given the model's performance in rapid deafferentation and the rapid effects of homeostatic mechanisms meant to keep

neural firing within its optimal dynamic range [28]. Similar phenomena have been described in the auditory system. Indeed, most investigations of musical hallucinations have focused on their tendency to arise in the context of deafferentation of the central auditory processing hierarchy via sensory deprivation or, most commonly, progressive sensorineural hearing loss [35–37]. However, recent work has investigated musical hallucinations occurring in the setting of cochlear implantation [38, 39]. In the most recent study only 7 of the 18 patients reporting musical hallucinations had such experiences before cochlear implantation [38]. The remainder (61%) developed the phenomenon following the operation. Of these 7, many reported that cochlear implant placement had made the musical hallucinations less prominent, but 2 reported that they became louder with implantation [38]. We speculate that implantation introduces new sensory inputs that have yet to be properly accommodated by top-down priors and, during that process, musical hallucinations arise as attempts to accommodate the new inputs in a system accustomed to the absence of bottom-up information. If true, this process would predict the observation

of hallucinations in ketamine under conditions of sparse sensory input, as described here.

With this framework in mind we may return to the case reports reviewed in the introduction and in table 1. It is notable that most reports of true hallucinatory phenomena follow emergence from higher-dose ketamine anesthesia (as reviewed in Introduction). In those studies employing placebo-controlled subanesthetic ketamine it is often unclear whether reports and ratings of hallucinations were in fact illusions (distortions of stimuli that were actually present [10]). However, among the 10 studies of controlled ketamine administration listed, we may identify 4 that reported the occurrence of true hallucinations in any sensory modality [9, 11, 40, 41]. The first of these studies [41] took place in a PET scanner and reported complex visual (but not auditory) hallucinations. Given the relatively quiet and visually open nature of PET scans compared with MRI scanners, this observation may be consistent with the model proposed here. Lahti et al. [40] administered ketamine to individuals with a diagnosis of schizophrenia and to typically developing controls. Crucially, while controls were noted not to experience true hallucinations, patients were noted to experience well-formed hallucinations (such as voices) – a fact that may be related to altered dopaminergic signaling in these individuals. Similar conclusions on the role of neuro-modulators in hallucinations may be drawn from the investigation by Gouzoulis-Mayfrank et al. [9] of the psychological impact of S-ketamine and the serotonergic hallucinogen N,N-dimethyltryptamine (DMT), which highlighted the relative prevalence of visual hallucinations and pervasiveness of auditory hallucinations during DMT administration, with only one occurrence of visual hallucination (cartoons running across a computer screen), during S-ketamine administration at the highest dose tested. Unfortunately, a washout period was included and no effect of order was observed, although given the model proposed here one may speculate that the prevalence of hallucinations under ketamine would increase even in subclinical plasma concentrations of DMT. Lastly, Bowdle et al. [11] conducted a single-blind placebo-controlled crossover study with controlled plasma concentrations of ketamine and noted that plasma concentration of ketamine correlated significantly with a visual analog scale rating on the item ‘I heard voices or sounds that were not real’, but findings were not elaborated upon beyond this and no details are available in the manuscript detailing the environment in which participants produced these ratings. Similarly, scanty detail regarding the environmental stimulus level is made available in those

studies definitively noting the absence of true hallucinations in the presence of ketamine.

The data analyzed here are derived from only one of several studies in which ketamine was administered during fMRI data acquisition. Unfortunately, the majority of these [42–49] do not specifically address perceptual abnormalities in subjects, providing only general PANSS scores. Other studies, similar to those noted above, do report an increased rate of auditory perceptual abnormalities under ketamine but do not differentiate between frank hallucinations and sensory distortions or illusions [50, 51]. Two studies have specifically commented on the occurrence of hallucinations in an fMRI setting [52, 53], noting an increased rate of perceptual abnormalities during ketamine administration, but both separately describing an absence of frank hallucinations in subjects. It is notable that in both studies the ketamine infusion rate (target plasma concentration of 100 ng/ml [52] and continuous infusion of 0.25 mg/kg/h) was markedly lower than that used here (0.58 mg/kg/h) and may represent a dose-related manipulation of the system we propose – as NMDA blockade/AMPA potentiation increases with dose, so do the prediction error signals propagated up the hierarchy, further increasing the need for top-down influence to explain them and resulting in hallucinations. However, further studies will be required to fully test the effect of ketamine dose upon hallucination propensity under conditions of relative sensory deprivation.

We note that the observations made here pertain to acute intoxication with ketamine. Less is known about chronic exposure. Lim [54] described a case series of 2 patients with chronic exposure to ketamine, averaging 4–5 months, who report enhanced sensation of environmental stimuli (e.g. taste, smells, music) observed in many acute studies but also report the occurrence of true auditory, visual and tactile hallucinations with chronic use. Chronic exposure leads to tolerance to subanesthetic ketamine [55]. In prior work we speculated that acute and chronic ketamine differ in their impact on processes of learning and inference [29]. That is, acute ketamine is transient and reversible. As such, it impacts sensory inferences and, whilst on board, vitiates perception. However, as it is metabolized, its synaptic effects subside and it does not have long-lasting effects on learning (it does not engender long-term changes in perceptual priors). However, chronic ketamine abuse appears not only to engage homeostatic changes in glutamate signaling, but it also alters slower monoaminergic and cholinergic function [56, 57]. These neuromodulators appear to code the gain

on perceptual and learning prediction errors, that is, the volatility or expected uncertainty of those parameters. Longer-term changes in those parameters may broaden the perceptual possibility space and induce what Hoffman has referred to as a 'listening attitude' – broadly, once a threshold of hallucinatory experiences has been surpassed, the patient 'expects' to hallucinate (although not necessarily consciously). We believe this process is dopamine driven and secondary to prolonged aberrant glutamate and GABA signaling [27, 29]. D₂ dopamine antagonists do not reverse the acute effects of ketamine [58]. However, consistent with our hypothesis, D₂ antagonism does seem to ameliorate symptoms in ketamine abuse [59].

In summary, we report qualitative and quantitative data that suggest ketamine administration in the MRI scanner induces auditory hallucinations at a dose that would not induce such symptoms outside of the scanner. We believe that this observation may have a bearing on our use of ketamine to model psychotic symptoms and our understanding of those symptoms in terms of the balance between top-down and bottom-up signaling in the Bayesian brain.

References

- 1 Luby ED, et al: Study of a new schizophreno-mimetic drug: sernyl. *AMA Arch Neurol Psychiatry* 1959;81:363–369.
- 2 Krystal JH, et al: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry* 1994;51:199–214.
- 3 Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. *Am J Psychiatry* 1991;148:1301–1308.
- 4 Javitt DC, Freedman R: Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. *Am J Psychiatry* 2015;172:17–31.
- 5 Slade PD, Bentall RP: *Sensory Deception: A Scientific Analysis Of Hallucination*. The Johns Hopkins Series in Contemporary Medicine and Public Health. Baltimore, Johns Hopkins University Press, 1988, p 275.
- 6 Wing JK, Cooper JE, Sartorius N: *Measurement and Classification of Psychiatric Symptoms*. An Instruction Manual for the PSE and Catego Program. London/New York, Cambridge University Press, 1974, p 233.
- 7 Lawes TGG: Schizophrenia, 'sernyl' and sensory deprivation. *Br J Psychiatry* 1963;109:243–250.
- 8 Pomarol-Clotet E, et al: Psychological effects of ketamine in healthy volunteers. Phenomenological study. *Br J Psychiatry* 2006;189:173–179.
- 9 Gouzoulis-Mayfrank E, et al: Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, crossover study in healthy volunteers. *Pharmacopsychiatry* 2005;38:301–311.
- 10 Newcomer JW, et al: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. *Neuropsychopharmacology* 1999;20:106–118.
- 11 Bowdle TA, et al: Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. *Anesthesiology* 1998;88:82–88.
- 12 Stone JM, Pilowsky LS: Psychopathological consequences of ketamine. *Br J Psychiatry* 2006;189:565–566.
- 13 Domino EF, Chodoff P, Corssen G: Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. *Clin Pharmacol Ther* 1965;6:279–291.
- 14 Overall JE: The Brief Psychiatric Rating Scale in psychopharmacology research; in Olivier-Martin PPR (ed): *Psychological Measurements in Psychopharmacology*. Oxford, Karger, 1974, p 267.
- 15 Shaw IH, Moffett SP: Ketamine and video nasties. *Anaesthesia* 1990;45:422.
- 16 Rasmussen KG: Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control. *Acta Neuropsychiatr* 2014;26:230–233.
- 17 Perel A, Davidson JT: Recurrent hallucinations following ketamine. *Anaesthesia* 1976;31:1081–1083.
- 18 Meyers EF, Charles P: Prolonged adverse reactions to ketamine in children. *Anesthesiology* 1978;49:39–40.
- 19 Fine J, Finestone SC: Sensory disturbances following ketamine anesthesia: recurrent hallucinations. *Anesth Analg* 1973;52:428–430.
- 20 Corlett PR, et al: Ketamine effects on memory reconsolidation favor a learning model of delusions. *PLoS One* 2013;8:e65088.
- 21 Anticevic A, et al: NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. *Proc Nat Acad Sci USA* 2012;109:16720–16725.
- 22 Driesen NR, et al: Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. *Mol Psychiatry* 2013;18:1199–1204.

Acknowledgments

A.R. Powers 3rd was supported by the Integrated Mentored Patient-Oriented Research Training (IMPORT) in Psychiatry grant (5R25MH071584-07) as well as the Clinical Neuroscience Research Training in Psychiatry grant (5T32MH19961-14) from the NIMH. Additional support was provided by the Yale Detre Fellowship for Translational Neuroscience. Data from the original study were obtained with the support of the Wellcome Trust and the Bernard Wolfe Health Neuroscience fund. The study was conducted at the Wellcome Trust Clinical Research Facility and the Wolfson Brain Imaging Centre (Addenbrooke's Hospital, Cambridge, UK) and within the Behavioral and Clinical Neuroscience Institute supported by the Medical Research Council and the Wellcome Trust. P.R. Corlett was supported by the Connecticut State Department of Mental Health and Addiction Services. He was funded by an IMHRO/Janssen Rising Star Translational Research Award and CTSA grant (UL1 TR000142) from the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Science (NCATS), components of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. The contents of the study are solely the responsibility of the authors and do not necessarily represent the official view of the NIH.

Disclosure Statement

P.R. Corlett consults for Otsuka Pharmaceuticals.

- 23 Perry EB Jr, et al: Psychiatric safety of ketamine in psychopharmacology research. *Psychopharmacology* 2007;192:253–260.
- 24 Krystal JH, et al: Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. *Biol Psychiatry* 2000;47:137–143.
- 25 Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;13:261–276.
- 26 Friston KJ: Hallucinations and perceptual inference. *Behav Brain Sci* 2005;28:764.
- 27 Corlett PR, Frith CD, Fletcher PC: From drugs to deprivation: a Bayesian framework for understanding models of psychosis. *Psychopharmacology (Berl)* 2009;206:515–530.
- 28 Reichert DP, Series P, Storkey AJ: Charles Bonnet syndrome: evidence for a generative model in the cortex? *PLoS Comput Biol* 2013;9:e1003134.
- 29 Corlett PR, et al: Glutamatergic model psychoses: prediction error, learning, and inference. *Neuropsychopharmacology* 2011;36:294–315.
- 30 Moran RJ, et al: Losing control under ketamine: suppressed cortico-hippocampal drive following acute ketamine in rats. *Neuropsychopharmacology* 2015;40:268–277.
- 31 Schmidt A, et al: Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. *Neuropsychopharmacology* 2012;37:865–875.
- 32 Plourde G, Baribeau J, Bonhomme V: Ketamine increases the amplitude of the 40-Hz auditory steady-state response in humans. *Br J Anaesth* 1997;78:524–529.
- 33 Herrero JL, et al: Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. *Nature* 2008;454:1110–1114.
- 34 Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. *Am J Psychiatry* 2003;160:13–23.
- 35 Berrios GE: Musical hallucinations. A historical and clinical study. *Br J Psychiatry* 1990;156:188–194.
- 36 Aziz VM, Asaad M: Musical hallucination in acquired and pre-lingual deafness. *Int Psychogeriatr* 2011;23:1015–1017.
- 37 Mahendran R: The psychopathology of musical hallucinations. *Singapore Med J* 2007;48:e68–e70.
- 38 Low WK, et al: Musical ear syndrome in adult cochlear implant patients. *J Laryngol Otol* 2013;127:854–858.
- 39 Auffarth IS, Kropp S: Musical hallucination in a patient after cochlear implantation. *J Neuropsychiatry Clin Neurosci* 2009;21:230–231.
- 40 Lahti AC, et al: Effects of ketamine in normal and schizophrenic volunteers. *Neuropsychopharmacology* 2001;25:455–467.
- 41 Vollenweider FX, et al: Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). *Eur Neuropsychopharmacol* 1997;7:25–38.
- 42 Musso F, et al: Ketamine effects on brain function – simultaneous fMRI/EEG during a visual oddball task. *Neuroimage* 2011;58:508–525.
- 43 Honey GD, et al: Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. *Cereb Cortex* 2005;15:749–759.
- 44 Corlett PR, et al: Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. *Arch Gen Psychiatry* 2006;63:611–621.
- 45 Fu CH, et al: Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance imaging study. *Psychopharmacology (Berl)* 2005;183:92–102.
- 46 Daumann J, et al: Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. *J Psychopharmacol* 2010;24:1515–1524.
- 47 Abel KM, et al: Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. *Neuroreport* 2003;14:387–391.
- 48 Abel KM, et al: Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. *Hum Brain Mapp* 2003;18:135–145.
- 49 Nagels A, et al: Effects of ketamine-induced psychopathological symptoms on continuous overt rhyme fluency. *Eur Arch Psychiatry Clin Neurosci* 2012;262:403–414.
- 50 Northoff G, et al: NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. *Schizophr Res* 2005;72:235–248.
- 51 Daumann J, et al: Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT_{2A} agonist and NMDA antagonist model of psychosis. *Psychopharmacology (Berl)* 2008;200:573–583.
- 52 Honey GD, et al: Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. *J Neurosci* 2008;28:6295–6303.
- 53 Deakin JF, et al: Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. *Arch Gen Psychiatry* 2008;65:154–164.
- 54 Lim DK: Ketamine associated psychedelic effects and dependence. *Singapore Med J* 2003;44:31–34.
- 55 Pouget P, et al: Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. *Psychopharmacology (Berl)* 2010;209:313–318.
- 56 Nelson CL, et al: Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. *Psychopharmacology (Berl)* 2002;161:168–179.
- 57 Morgan CJ, Muetzelfeldt L, Curran HV: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. *Addiction* 2010;105:121–133.
- 58 Krystal JH, et al: Interactive effects of sub-anesthetic ketamine and haloperidol in healthy humans. *Psychopharmacology (Berl)* 1999;145:193–204.
- 59 Giannini AJ, Underwood NA, Condon M: Acute ketamine intoxication treated by haloperidol: a preliminary study. *Am J Ther* 2000;7:389–391.
- 60 Oye I, Paulsen O, Maurset A: Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. *J Pharmacol Exp Ther* 1992;260:1209–1213.